EUVIMEDEUVIMED entdecken
Crossref

Duration of Concurrent Oxycodone and Selective Serotonin Reuptake Inhibitors Use and the Risk of Opioid Overdose

Chijioke Okeke iD, Olajumoke Olateju, Ismaeel Yunusa iD, Prachet Bhatt, James Douglas Thornton

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280251372646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Chijioke Okeke und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Oxycodone, Selective Serotonin Reuptake Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors, Opiate Overdose. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Concurrent use of oxycodone and strong cytochrome P450 2D6 (CYP2D6)-inhibiting selective serotonin reuptake inhibitors (SSRIs), specifically paroxetine and fluoxetine, is associated with the risk of opioid overdose.

Objective

This study assessed the association between the duration of concurrent oxycodone and CYP2D6-inhibiting SSRI use and overdose risk.

Methods

A retrospective cohort study conducted using the Merative MarketScan claims database from January 1, 2017, to December 31, 2019. Adults aged ≥18 years with private insurance who initiated both oxycodone and SSRIs were included. Patients were grouped as (1) oxycodone with other SSRIs (reference); (2) oxycodone with paroxetine or fluoxetine with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxycodoneSelective Serotonin Reuptake InhibitorsCytochrome P-450 CYP2D6 InhibitorsOpiate OverdoseAnalgesics, OpioidHumansFemaleMaleMiddle AgedRetrospective StudiesAdultParoxetineFluoxetineTime FactorsYoung AdultDrug Therapy, CombinationCohort StudiesProportional Hazards Models

Stichwörter der Autor:innen

cytochrome enzymefluoxetineopioidsoverdoseoxycodoneparoxetineselective serotonin reuptake inhibitors

Substanzen

OxycodoneSelective Serotonin Reuptake InhibitorsCytochrome P-450 CYP2D6 InhibitorsParoxetineFluoxetineAnalgesics, Opioid

Autor:innen und Institutionen

  • The Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston, TX, USA.
  • Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA.
  • Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC, USA.

ORCID-Profile: Chijioke Okeke, Ismaeel Yunusa

Zitieren

APA

Okeke, C., Olateju, O., Yunusa, I., Bhatt, P., & Thornton, J. D. (2025). Duration of Concurrent Oxycodone and Selective Serotonin Reuptake Inhibitors Use and the Risk of Opioid Overdose. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251372646

Vancouver

Okeke C, Olateju O, Yunusa I, Bhatt P, Thornton JD. Duration of Concurrent Oxycodone and Selective Serotonin Reuptake Inhibitors Use and the Risk of Opioid Overdose. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251372646

BibTeX
@article{Okeke2025,
  author = {Okeke, Chijioke and Olateju, Olajumoke and Yunusa, Ismaeel and Bhatt, Prachet and Thornton, James Douglas},
  title = {Duration of Concurrent Oxycodone and Selective Serotonin Reuptake Inhibitors Use and the Risk of Opioid Overdose},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280251372646}
}
Kostenlos starten →